Cases
Endo International, PLC
Securities Class Action
Overview
Overview
- Date:
- 10/11/2017
- Company Name:
- Endo International, PLC
- Stock Symbol:
- ENDP
- Class Period:
- FROM 11/30/2012 TO 7/6/2017
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Eastern District of Pennsylvania
NEW YORK, October 11, 2017 – Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Endo International, PLC (NASDAQ: ENDP) securities between November 30, 2012 and July 6, 2017 (the “Class Period”). Investors have until October 17, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you purchased or otherwise acquired Endo securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you purchased or otherwise acquired Endo securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.